Lab resourceScutellarin attenuates vasospasm through the Erk5-KLF2-eNOS pathway after subarachnoid hemorrhage in rats

- Scutellarin alleviated neurological deficits after subarachnoid hemorrhage (SAH).
- Scutellarin alleviated vasospasm after SAH.
- Scutellarin increased endothelial NOS (eNOS) expression after SAH.
- Scutellarin increased the expressions of p-Erk5 and Kruppel-like factor 2 (KLF2) after SAH.
- Erk5 inhibition abolished the above effects of scutellarin after SAH.

Angiographic vasospasm, especially in the early phases (<72 h) of subarachnoid hemorrhage (SAH), is one of the major complications after an aneurysm rupture and is often the cause of delayed neurological deterioration. Scutellarin (SCU), a flavonoid extracted from the traditional Chinese herb Erigeron breviscapus, has been widely accepted as an antioxidant, but the effect of SCU on vasospasm after SAH remains elusive. Endovascular perforation was conducted to induce SAH in Sprague-Dawley rats. Then, the underlying mechanism of the anti-vasospasm effect of SCU was investigated using a modified Garcia scale, India ink angiography, cross-sectional area analysis, immunohistochemistry staining and western blot. SCU (50 μM, 100 mg/kg) alleviated angiographic vasospasm and improved neurological function 48 h after SAH and enhanced the expression of endothelial nitric oxide synthase (eNOS) at the intima of cerebral arteries. In addition, SCU upregulated the expression of phosphorylated extracellular-regulated kinase 5 (p-Erk5) and Kruppel-like factor 2 (KLF2) at 48 h after SAH. However, the effects of SCU were reversed by the Erk5 inhibitor XMD8-92. Our results indicate that SCU could attenuate vasospasm and neurological deficits via modulating the Erk5-KLF2-eNOS pathway after SAH, which may provide an experimental basis for the clinical use of SCU treatment in SAH patients.